BioWorld

Aug. 13, 2003

Lilly Drops Out Of One Program With Emisphere, Stays In Another

Emisphere Technologies Inc. lost a partner for one oral hormone replacement therapy but will continue to work in tandem on another oral hormone program. (BioWorld Today) Read More

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Missing Out On Sunlight, Dietary Calcium, Vitamin D, Some North American Infants Getting Rickets

QLT Raises $150M In Notes Sale, Plans $50M Buyback Of Stock

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Handshake, businessmen holding dollar sign, lightbulb

Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

BioWorld

A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...